Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB2450 plus anlotinib versus pembrolizumab as first-line treatment for advanced non-small cell lung cancer
CTR20212409Phase 3Active
- Sponsor
- Nanjing Shunxin Pharmaceutical
- Start
- Aug 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of benmelstobart, anlotinib, pembrolizumab in non-small cell lung cancer (NSCLC), sponsored by Nanjing Shunxin Pharmaceutical. Started Aug 2021; status: active.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20212409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212409.